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OBJECTIVES We sought to evaluate the effects of spironolactone on neurohumoral factors and left
ventricular remodeling in patients with congestive heart failure (CHF).
BACKGROUND Aldosterone (ALD) promotes collagen synthesis and structural remodeling of the heart.
Spironolactone, an ALD receptor antagonist, is reported to reduce mortality in patients with
CHF, but its influence on left ventricular remodeling has not been clarified.
METHODS Thirty-seven patients with mild-to-moderate nonischemic CHF were randomly divided into
two groups that received treatment with spironolactone (n 5 20) or placebo (n 5 17). We
measured left ventricular volume and mass before treatment and after four months of
treatment. We also measured the plasma levels of neurohumoral factors, such as atrial
natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as well as plasma procollagen
type III aminoterminal peptide (PIIINP), a marker of myocardial fibrosis.
RESULTS Left ventricular volume and mass were significantly decreased and ejection fraction was
significantly increased in the spironolactone group, while there were no changes in the
placebo group. Plasma levels of ANP, BNP and PIIINP were significantly decreased after
spironolactone treatment, but were unchanged in the placebo group. There was a significant
positive correlation between the changes of PIIINP and changes of the left ventricular volume
index (r 5 0.45, p 5 0.045) as well as the left ventricular mass index (r 5 0.65, p 5 0.0019)
with spironolactone treatment.
CONCLUSIONS These findings indicate that four months of treatment with spironolactone improved the left
ventricular volume and mass, as well as decreased plasma level of BNP, a biochemical marker
of prognosis and/or ventricular hypertrophy, suggesting that endogenous aldosterone has an
important role in the process of left ventricular remodeling in nonischemic patients with
CHF. (J Am Coll Cardiol 2001;37:1228–33) © 2001 by the American College of
Cardiology
Despite the outstanding success achieved with angiotensin-
converting enzyme (ACE) inhibitors in the treatment of
congestive heart failure (CHF), the mortality rate remains
relatively high; this high mortality rate is partly due to the
aldosterone (ALD) escape phenomenon in patients being
treated with ACE inhibitors (1–4). Recently, spironolac-
tone was shown to reduce the mortality of patients with
CHF who had already received ACE inhibitors, digitalis
and diuretics. In the Randomized Aldactone Evaluation
Study (RALES) (3,5), both sudden death and death from
CHF were significantly reduced by spironolactone therapy.
However, despite the great impact of these findings, the
mechanism by which spironolactone improves mortality
remains to be fully elucidated.
Aldosterone has both myocardial and renal effects that
may have profound implications for left ventricular remod-
eling (6). A significant association has been found between
plasma ALD and left ventricular mass in patients with
hypertension as well as in a population-based sample,
suggesting that ALD may be important in the modulation
of cardiac structure (7–9). Recently, it was reported that the
mineralocorticoid receptor, which mediates the action of
ALD, is expressed in cardiomyocytes, endothelial cells and
fibroblasts in the human heart (10–12). Aldosterone is
secreted from the adrenal glands, and has been shown to
stimulate cardiac collagen synthesis and fibroblast prolifer-
ation via activation of local mineralocorticoid receptors or an
unexplained indirect mechanism (13–16).
Plasma levels of cardiac natriuretic peptides such as atrial
natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) are increased in patients with CHF and are useful
prognostic predictors, especially BNP (17–20) which is a
ventricular hormone (21). The usefulness of plasma BNP is
partly due to the fact that high BNP levels are significantly
correlated with hemodynamic abnormalities of the left
ventricular ejection fraction (LVEF) and left ventricular
end-diastolic pressure (21,22). Treatment of CHF based on
the plasma aminoterminal BNP level was recently reported
to reduce cardiovascular events (23).
In the present study, we evaluated left ventricular volume
and mass, as well as plasma levels of neurohumoral factors,
such as ANP and BNP, before and after four months of
treatment with spironolactone or placebo.
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METHODS
Patients. We studied 37 patients with stable symptomatic
CHF (New York Heart Association [NYHA] functional
class II or III) and LVEF ,45%. There were 29 men and
eight women (mean age, 64 years). The cause of heart
failure was dilated cardiomyopathy in 28 patients, hyper-
tensive heart disease in six patients and valvular heart disease
in three patients. Patients were excluded if they had coro-
nary artery disease, renal failure, hyperkalemia or liver
dysfunction. Informed consent was obtained from all pa-
tients before participation in the study, and the protocol was
approved by the Human Investigations Committee of our
institution. Twenty-six patients were in NYHA functional
class II and 11 patients were in class III. On enrollment in
the study, 24 patients were being treated with diuretics, 27
with ACE inhibitors, 27 with digitalis, 14 with beta-
blockers, and three with angiotensin II type-1 receptor
blockers. Most of these drugs had been administered for .3
months.
Study protocol. This was a prospective randomized study.
All of the patients were in a stable condition for at least
three months before enrollment. The 37 patients with
mild-to-moderate symptomatic left ventricular dysfunction
were randomly divided into two groups that received treat-
ment with spironolactone (n 5 20) or placebo (n 5 17).
The dose of spironolactone was set at 25 mg once daily.
To measure the plasma levels of neurohumoral factors
and procollagen type III aminoterminal peptide (PIIINP),
blood samples were collected from an antecubital vein
following supine rest for at least 30 min before and after four
months of treatment with spironolactone or placebo. The
samples were collected 3 h after the morning dose of
medications, such as digitalis and diuretics, but before the
administration of spironolactone or placebo. When four
months of treatment had been completed, blood samples
were also collected 3 h after the morning dose of other
medications, including digitalis and diuretics, but without
spironolactone or placebo being administered. M-mode
echocardiography was also performed with two-dimensional
monitoring using a Sonolayer phased-array sector scanner
(model SSH-160A, Toshiba Co., Tokyo, Japan) in a
blinded fashion before and after four months of treatment
with spironolactone or placebo. Left ventricular volumes
were calculated using Teichholtz’s formula, and the LVEF
was determined. Left ventricular mass was calculated using
previously reported method (24).
Measurement of neurohumoral factors and PIIINP.
Blood for measurement of the plasma levels of ANP, BNP
and endothelin-1 was transferred to a chilled tube contain-
ing ethylenediaminetetraacetic acid (EDTA) (1 mg/ml) and
aprotinin (500 kallikrein inactivator U/ml), and then was
centrifuged at 3,000 rpm for 15 min at 4°C. Thus, the
plasma obtained was stored at 230°C until assay. Plasma
ANP and BNP concentrations were measured with a
specific immunoradiometric assay for alpha-human ANP
and human BNP, respectively, using a commercial kit
(Shionogi, Osaka, Japan), as previously reported (19). The
plasma endothelin-1 level was determined using an antibody
against synthetic endothelin-1 (Peninsula Laboratories,
Inc., Belmont, California) and 125I-labeled endothelin-1
(Amersham Japan, Tokyo, Japan), as previously reported
(25).
Blood for measurement of the plasma levels of norepi-
nephrine, plasma active renin concentration (PARC) and
ALD was transferred to a chilled tube containing EDTA (1
mg/ml) and centrifuged at 3,000 rpm for 15 min at 4°C,
after which the plasma thus obtained was stored at 230°C
until assay. The plasma norepinephrine concentration was
measured by high performance liquid chromatography,
while PARC and ALD levels were measured using com-
mercial radioimmunoassay kits. Plasma PIIINP levels were
measured with a specific immunoradiometric assay using a
commercial kit (CIS Bio International, Nagoya, Japan).
Statistical analysis. All results are expressed as the mean 6
SEM. Univariate analysis was performed using Student t
test. Categorical data were compared against a chi-squared
distribution. Linear regression analysis was used to deter-
mine the relationship between continuous variables. A p
value ,0.05 was regarded as significant.
RESULTS
Clinical characteristics. There were no differences in age,
gender, NYHA functional class, etiology of heart failure,
LVEF or medications on entry into the study between the
spironolactone group and the placebo group (Table 1).
Comparison of hemodynamics and neurohumoral factors
before and after treatment. There were no differences in
pretreatment heart rate, mean blood pressure, LVEF, left
ventricular volume index, left ventricular mass index and
plasma level of PIIINP between the spironolactone group
and the placebo group, and also no differences of pretreat-
ment neurohumoral factors, such as ANP, BNP,
endothelin-1, norepinephrine, PARC and ALD (Table 2).
In the placebo group, there were no significant changes in
these variables after four months. In the spironolactone
group, there were no significant changes in heart rate, mean
blood pressure and body weight, but there was improvement
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
ALD 5 aldosterone
BNP 5 brain natriuretic peptide
CHF 5 congestive heart failure
EDTA 5 ethylenediaminetetraacetic acid
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PARC 5 plasma active renin concentration
PIIINP 5 procollagen type III aminoterminal peptide
RALES 5 Randomized Aldactone Evaluation Study
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of NYHA functional class (2.3 6 0.1 vs. 1.9 6 0.1, p 5
0.002) after four months of treatment. There was a signif-
icant difference in changes of the left ventricular end-
diastolic and end-systolic volume index and the left ventric-
ular mass index between the two groups (Fig. 1). There was
also a significant difference in changes in plasma level of
ALD, BNP and PIIINP between the two groups (Fig. 2).
Relationship between left ventricular volume index, left
ventricular mass index and PIIINP before and after
spironolactone treatment. There was significant positive
correlation between changes of the plasma PIIINP level and
changes of the left ventricular mass index (r 5 0.65, p 5
0.0019) (Fig. 3) or the left ventricular volume index (r 5
0.45, p 5 0.045) with spironolactone treatment. In contrast,
there was no relationship between these parameters in the
placebo group.
DISCUSSION
We recently reported that the heart is a target organ for
ALD, and that spironolactone (a mineralocorticoid receptor
antagonist) inhibits the ALD extraction through the heart
in patients with CHF (26). We also found a positive
correlation between the transcardiac ALD extraction and
the plasma level of PIIINP (26), a possible biochemical
marker of myocardial fibrosis (27,28), suggesting that the
increase in ALD extraction by the failing heart might
stimulate myocardial collagen turnover, as occurs in vitro
(29). However, to our knowledge, serial measurements of
neurohumoral factors as well as the left ventricular volume
and mass have never been done before and after long-term
treatment with spironolactone. The present study demon-
strated for the first time that four months of treatment with
spironolactone could improve left ventricular volume and
mass index, as well as reduce plasma levels of BNP and
PIIINP in patients with nonischemic CHF. The reduction
of left ventricular volume and mass may have been due to
blocking the mineralocorticoid receptor, which is known to
be expressed in the human heart (14,15), since blood
pressure and body weight did not change after spironolac-
tone therapy.
Plasma ANP and BNP are useful prognostic predictors in
patients with CHF, especially the level of BNP (17–20)
since it is a ventricular hormone (21). The plasma BNP level
was reported to be correlated with hemodynamic abnormal-
ities of the LVEF and left ventricular end-diastolic pressure
(21,22) as well as left ventricular mass (30). Therefore, the
decrease of plasma BNP after treatment with spironolactone
was due to the decreased left ventricular filling pressure,
improvement of left ventricular remodeling or both. The
decrease of BNP with spironolactone therapy may have
reflected improvement of left ventricular diastolic function
secondary to the effects of this drug on cardiac hypertrophy
Table 2. Comparison of Hemodynamics and Neurohumoral Factors Before and After Treatment
in 37 Patients With Congestive Heart Failure Divided Into Two Groups: Spironolactone
or Placebo
Placebo (n 5 17) Spironolactone (n 5 20)
Baseline 4 months Baseline 4 months
HR (beats/min) 66.4 6 1.9 64.8 6 1.8 72.3 6 3.6 70.6 6 3.0
MBP (mm Hg) 90 6 2.4 90.5 6 2.8 88 6 2.5 85.5 6 2.4
LVEF (%) 36.6 6 1.6 36.3 6 1.7 32.2 6 2.2 35 6 1.9*
LVEDVI (ml/m2) 169 6 15 170 6 17 192 6 11 178 6 10*
LVM index (g/m2) 150 6 10 151 6 11 158 6 7.8 147 6 7.5*
PIIINP (U/ml) 0.57 6 0.04 0.57 6 0.05 0.64 6 0.04 0.48 6 0.03**
ANP (pg/ml) 67 6 23 65 6 23 70.9 6 25.5 43.2 6 17*
BNP (pg/ml) 195 6 59 172 6 50 200 6 66 89.7 6 27**
PARC (pg/ml) 234 6 96 260 6 66 93 6 26 141 6 56*
ALD (pg/ml) 88 6 14 78 6 8.5 61 6 8 106 6 16*
Norepinephrine (pg/ml) 443 6 47 407 6 37 382 6 41 409 6 43
Endothelin-1 (pg/ml) 2.9 6 0.2 2.8 6 0.2 2.8 6 0.2 2.5 6 0.2
*p , 0.05; **p , 0.01 versus baseline value of the spironolactone group.
ALD 5 aldosterone; ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; HR 5 heart rate; LVEDVI 5 left
ventricular end-diastolic volume; LVEF 5 left ventricular ejection fraction; LVM 5 left ventricular mass; MBP 5 mean arterial
blood pressure; PARC 5 plasma active renin concentration; PIIINP 5 procollagen type III aminoterminal peptide.
Table 1. Clinical Characteristics of Patients in the
Spironolactone and Placebo Groups
Spironolactone
(n 5 20)
Placebo
(n 5 17)
p
Value
Age (yr) 62.7 6 2.8 65.0 6 3.4 NS
Gender (male/female) 15/5 13/4 NS
Etiology of left ventricular dysfunction
Dilated cardiomyopathy 15 13 NS
Hypertensive heart disease 4 2 NS
Valvular heart disease 1 2 NS
NYHA functional class
II 14 8 NS
III 6 3 NS
Left ventricular ejection fraction (%) 32.2 6 2.2 36.6 6 1.6 NS
Treatment
Furosemides 12 12 NS
Digitalis 12 15 NS
ACE inhibitors 14 13 NS
Beta-blockers 9 5 NS
ACE 5 angiotensin-converting enzyme; NS 5 not significant; NYHA 5 New York
Heart Association.
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and fibrosis. Treatment of CHF guided by the plasma
aminoterminal BNP level has been reported to reduce
cardiovascular events (23), so the decrease of BNP may be
associated with a beneficial outcome as was the case in the
RALES study (5).
The plasma PIIINP level may be a biochemical marker of
myocardial fibrosis and/or left ventricular remodeling in
patients with CHF (26–28). In our previous study (26),
there was a positive correlation between the plasma PIIINP
level and the left ventricular end-diastolic volume index and
between the transcardiac ALD extraction and the plasma
PIIINP level, suggesting an interaction between ALD
extraction and left ventricular remodeling in patients with
CHF. In the present study, plasma PIIINP was significantly
decreased after spironolactone therapy, which was consis-
tent with the previous study (31), and there was a significant
positive correlation between the changes of PIIINP and the
changes of left ventricular volume and mass with spirono-
lactone treatment. Although the cause and effect of the
relationship between the changes in PIIINP and the
changes in left ventricular volume and mass remain un-
known, the present study suggests that PIIINP is a useful
marker of the effect of spironolactone on left ventricular
remodeling.
An increase of PARC and ALD has been observed with
spironolactone therapy, suggesting blockade of ALD recep-
tors and loss of negative feedback inhibition (32). In the
present study, the plasma levels of norepinephrine and
endothelin-1 were not changed after spironolactone ther-
apy, but we cannot deny the possibility that spironolactone
may increase cardiac norepinephrine uptake and improve
cardiac sympathetic activity in patients with CHF (32).
Study limitations. In the present study, patients with
CHF secondary to coronary artery disease were excluded,
since it is difficult to evaluate left ventricular volume and
mass in such patients. Therefore, further studies are needed
to assess the effects of spironolactone in patients with
ischemic cardiomyopathy. In addition, the small number of
patients with nonischemic CHF was also a limitation of the
present study. The present study employed a fixed spirono-
lactone dose of 25 mg/d, therefore, the dose-response effect
of spironolactone on left ventricular remodeling and BNP
must also be evaluated.
CONCLUSIONS
Plasma levels of ANP, BNP and PIIINP were significantly
decreased after four months of spironolactone treatment,
but did not change in the placebo group. There was a
significant positive correlation between the changes of
PIIINP and the changes of left ventricular volume and mass
with spironolactone therapy. These findings indicate that
Figure 1. Absolute changes from the baseline in left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index
(LVESVI) and left ventricular mass index (LVMI) before and after treatment with placebo or spironolactone for four months in patients with
mild-to-moderate congestive heart failure. *p , 0.05; **p , 0.01 versus placebo.
Figure 2. Absolute changes from the baseline in plasma levels of aldosterone (ALD), brain natriuretic peptide (BNP), and procollagen type III
aminoterminal peptide (PIIINP) before and after treatment with placebo or spironolactone for four months in patients with mild-to-moderate congestive
heart failure. *p , 0.05; **p , 0.01 versus placebo.
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long-term spironolactone treatment can improve left ven-
tricular remodeling and decrease the plasma level of BNP, a
biochemical marker of prognosis and/or ventricular hyper-
trophy, in patients with nonischemic CHF.
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